Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. - Wikidata - awgldk - TriplyDB

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q38177173

about

Clinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patients The durability of sitagliptin in elderly patients with type 2 diabetes.Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.Antihyperglycaemic therapies and cancer risk.Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.A review of gliptins for 2014.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.Sitagliptin: A Review in Type 2 Diabetes.Rhabdomyolysis and AKI with Atorvastatin and Sitagliptin Use in the Setting of Low 25-Hydroxyvitamin D Levels.Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.SDF-1α (Stromal Cell-Derived Factor 1α) Induces Cardiac Fibroblasts, Renal Microvascular Smooth Muscle Cells, and Glomerular Mesangial Cells to Proliferate, Cause Hypertrophy, and Produce Collagen.GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose.Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.

P2860

Q28083144-C9968658-4ED0-44ED-855C-CEEEE87DB6E5 Q34511545-9E99BEB3-800D-4A3A-939E-3737281C7365 Q36856980-2E325369-0CD3-42D3-85BE-3675DE23A3E3 Q37227397-8C5D1C1D-D913-4D4A-8D3F-2D82A808A6C9 Q38212007-967DC161-7387-4542-9EC4-58196E213803 Q38250719-9B1FABBC-B8F9-4B1B-9902-C9C87B89DE20 Q38261573-BC17579D-7347-431A-B823-5F1C7BCAE802 Q38266290-1AC3C76D-92C7-4726-AA7F-5B6DF3F329F0 Q38335751-54182963-4C79-44EE-BA22-1F2E2F9E588D Q38902321-37230511-758F-472C-B719-A56F25C7EF75 Q39063447-B0F938C1-31C7-4338-8761-F0175D13B0F0 Q39081543-8466741C-996B-4423-9E65-811F9725C71C Q39434470-FE4B3F50-F84C-488F-B3DC-875837E54026 Q40492085-5103FAF9-71DA-4689-B428-81AFB936D8A5 Q42876331-CBBFDB1F-2BDA-428E-B397-45552EB8A8B7 Q47121177-5C9AD59E-C724-4C0B-80F1-088609E4D2E2 Q49414493-7DE0A44A-828F-40ED-B1E3-108739CDE9FC Q50997819-82D86EBE-C0E9-42AE-9118-EC156B500CD9 Q51226655-6434F68B-F9A8-4415-B5CF-AFEA60FEA30A

P2860

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q38177173

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.

@en

type

label

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.

@en

prefLabel

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.

@en

P1433

Q38177173-402F32CC-6399-4D6E-B755-D695A2C63AE1

P1476

Q38177173-3996D36E-822B-4373-9F0C-E62DFAC1798C

P2860

Q38177173-004520BC-78D6-4D24-8AC9-9140BE9606C3

Q38177173-03B2B1CF-2CBB-4397-B2FB-20611D9F6687

Q38177173-045C22A4-8A22-4020-810C-E12D63613953

Q38177173-0461CD91-89DF-4807-9FE9-30BCDDEF4154

Q38177173-04A4E10A-665C-4997-AA16-DF2DD6F919AA

Q38177173-06223702-4793-4B04-B4F3-688C2F37C1E8

Q38177173-06243A59-4F64-43A0-BE2E-F52AF3735350

Q38177173-07972831-3BD6-44C7-BF04-EC51CAC25671

Q38177173-0C5C7E7B-9912-49DA-BCAE-DF0AF77CAAC9

Q38177173-0D7B3E9E-8A12-4309-9F30-4C7EFAE23134

P2888

Q38177173-1F7867F1-D852-43BE-A6E7-76322E661805

P304

Q38177173-FDC5F8A3-A4D3-4478-A07D-08ED00577AFC

P31

Q38177173-6D463ECA-421A-4E0F-83B4-D2EB1321631E

P356

Q38177173-FD1EB69D-6ED4-4D06-99DB-26A57FB6FF80

P433

Q38177173-BEC0BE24-0E44-42D0-8259-D589B4D53F32

P478

Q38177173-5959995B-EE6F-4F40-9500-153464A2F992

P50

Q38177173-98BFD9F7-3527-4BAB-A236-41CA8C1FCF53

P577

Q38177173-C64CF254-D42D-4DFA-95D7-324304FD29D3

P6179

Q38177173-E3D10B5D-A3E9-4024-9519-DBCE23F7C0E3

P698

Q38177173-E7F75968-FBC9-4BE1-9605-6B0BFE9BC0FD

P356

S40265-013-0169-1

P1433

P1476

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.

@en

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Diagnosis and classification of diabetes mellitus

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

Standards of medical care in diabetes--2012

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

P2888

s40265-013-0169-1

P304

223-242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-013-0169-1

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1008322827

http://www.w3.org/2001/XMLSchema#string

P698

24407560

http://www.w3.org/2001/XMLSchema#string